Fortunately, in patients with the more common heterozygous FH (HeFH) who have at least one normal LDLR allele and therefore, residual functionality of the LDL receptor pathway, PCSK9 antibodies still cause marked reductions in LDL-C, comparable to the reductions observed in patients without proven HeFH. The gene discussed is LDLR; the disease is familial hyperaldosteronism.